All In Biotech

Drug Trial Radar · NCT00450437

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults

A Phase 3, Multi-center Study to Evaluate Lot to Lot Consistency, Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults and Compare to the Safety and Immune Response to a Licensed Conjugate Meningococcal ACWY Vaccine

Last checked: Nov 19, 2026Latest source record: Jan 28, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,539 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,539

Actual

Start

Mar 2007

Primary completion

Aug 2007

Study completion Jan 2008

Sponsor

Lead sponsor
Novartis VaccinesNovartis (NVS)
Sponsor type
Industry
First posted
Mar 22, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 11 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the lot to lot consistency, safety and immune response of the Novartis Meningococcal ACWY conjugate vaccine in healthy US adolescents and adults.

Conditions

  • Meningococcal Infections
  • Meningococcal Meningitis

Interventions

  • MenACWY CRMBiological

    One dose of the Novartis meningococcal ACWY conjugate vaccine was administered intramuscularly.

  • Meningococcal ACWY Conjugate vaccineBiological

    One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered intramuscularly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Lot to Lot Consistency of MenACWY as Measured by hSBA GMT Vaccine Group Ratios, Ages 11 to 18 YearsTime frame: 28 days after vaccination
  2. Percentage of Seroresponders, Ages 11 to 18 YearsTime frame: 28 days after vaccination
  3. Number of Participants With at Least One Severe Systemic Reaction, Ages 11 to 55 YearsTime frame: 6 days after vaccination
  4. Percentage of Seroresponders, Ages 19 to 55 YearsTime frame: 28 days after vaccination

Locations

40 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Tuscaloosa, Alabama

  • Site not named

    Fremont, California

  • Site not named

    Fresno, California

  • Site not named

    Hayward, California

  • Site not named

    Oakland, California

  • Site not named

    Roseville, California

  • Site not named

    Sacramento, California

  • Site not named

    San Jose, California

  • Site not named

    Denver, Colorado

  • Site not named

    Atlanta, Georgia

  • Site not named

    Marietta, Georgia

  • Site not named

    Woodstock, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Bardstown, Kentucky

  • Site not named

    Annapolis, Maryland

  • Site not named

    Baltimore, Maryland

  • Site not named

    Frederick, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Fall River, Massachusetts

  • Site not named

    Lebanon, New Hampshire

  • Site not named

    Akron, Ohio

  • Site not named

    Cincinnati, Ohio

  • Site not named

    South Euclid, Ohio

  • Site not named

    Carnegie, Pennsylvania

  • Site not named

    Erie, Pennsylvania

  • Site not named

    Greenville, Pennsylvania

  • Site not named

    Grove City, Pennsylvania

  • Site not named

    Harleyville, Pennsylvania

  • Site not named

    Jefferson Borough, Pennsylvania

  • Site not named

    Latrobe, Pennsylvania

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Sellersville, Pennsylvania

  • Site not named

    Uniontown, Pennsylvania

  • Site not named

    Upper Saint Clair, Pennsylvania

  • Site not named

    Washington, Pennsylvania

  • Site not named

    Wexford, Pennsylvania

  • Site not named

    Galveston, Texas

  • Site not named

    Salt Lake City, Utah

  • Site not named

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.